Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial - Blauvelt, A; Papp, K A; Griffiths, CE M (J Am Acad Dermatol, 2017)
et al.